Market News & Trends
Cytokinetics Announces Start of Phase II Clinical Trial
Cytokinetics, Inc. recently announced the start of a randomized, double-blind, placebo-controlled, two-period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107) on physical…
GeoVax Labs Announces Filing of IND Application for HIV Human Clinical Trial
GeoVax Labs, Inc. recently announced the filing of an Investigational New Drug (IND) application with the US FDA for the conduct of the next human…
CordenPharma Enters Oligonucleotide API Manufacturing Market to Further Strengthen CDMO Offering
CordenPharma recently announced its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing market. Dr. Christian Ewers, Vice President Operations, CordenPharma, indicated the…
LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca
LEO Pharma recently announced it is a significant step closer to realizing its vision of becoming the preferred dermatology care partner following a strategic partnership…
Tesaro Raises $377 Million
TESARO, Inc. recently announced it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans…
Merck Provides Results of Pivotal Study That Confirms Addition of Erbitux to FOLFOX Significantly Improves Outcomes
Merck presented data at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, the…
Aeterna Zentaris & Orient Europharma Sign License Agreement
Aeterna Zentaris Inc. and Orient EuroPharma Co., Ltd. recently announced the signing of an exclusive license agreement between the company and Cyntec Co., Ltd., an…
RiboMed Biotechnologies & Tocagen Collaborate to Analyze Epigenetic Prognostic Markers, Including MGMT, in Recurrent Brain Tumors
RiboMed Biotechnologies, Inc. and Tocagen Inc. recently announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair…
Relmada Therapeutics Secures First European Patent Covering LevoCap ER
Relmada Therapeutics, Inc. recently announced it has been granted a patent from the European Patent Office (EPO) for compositions and methods of use for its…
West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
On-body Infusor with Prefilled Cartridge to Deliver Monthly Single Dose of Repatha® (evolocumab) West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in…
Global Urological Cancers Market Will Double to $35.9 billion by 2022
The urological cancers market, including bladder, kidney, prostate, and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a…
Everon Biosciences Introduces New Age-Related Cellular Target That Changes Focus of Anti-Aging Drug Discovery
A research team from Everon Biosciences, Inc. and Roswell Park Cancer Institute has identified a specific subpopulation of immune cells accumulating in old mice that…
BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 With the PD-1 Antibody BGB-A317
BeiGene, Ltd. recently announced the dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, in…
Biogen & AbbVie’s Once-Monthly ZINBRYTA Approved in European Union
The European Commission (EC) has granted marketing authorization for ZINBRYTA (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen…
Intrexon & ZIOPHARM Amend Exclusive Channel Collaborations
Intrexon Corporation and ZIOPHARM Oncology, Inc. recently announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve…
Catalent to Commercially Supply Palatin Technologies’ New Bremelanotide FSD Product in Pen Injectors
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it…
Major Players in Type 2 Diabetes Shifting Focus to Pricing to Maintain Market Share
The highly mature type 2 diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will see pharmaceutical companies prioritizing competitive…
Catalent to Commercially Supply Palatin Technologies’ New Bremelanotide FSD Product in Pen Injectors
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it…
Major Players in Type 2 Diabetes Shifting Focus to Pricing to Maintain Market Share
The highly mature type 2 diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will see pharmaceutical companies prioritizing competitive…
XBiotech Signs Exclusive Licensing Agreement With Megapharm
XBiotech Inc., developer of next-generation True Human antibody therapies, recently announced that it has entered into an exclusive licensing agreement with Megapharm Ltd., to commercialize…
